Lexicon Announces INPEFA Use Associated With Early Clinical Benefit In Heart Failure And Atherosclerotic Events In Analysis Of Clinical Data
Portfolio Pulse from Benzinga Newsdesk
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced positive results from a post hoc analysis of the SCORED trial, showing early clinical benefits of INPEFA (sotagliflozin) in reducing heart failure and major adverse cardiovascular events (MACE) risks. The analysis, presented at the AHA Scientific Sessions 2023, indicated significant risk reductions as early as three months after treatment. INPEFA was approved by the FDA on May 26, 2023, for reducing cardiovascular risks in adults with heart failure or type 2 diabetes with additional risk factors.
November 12, 2023 | 10:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lexicon Pharmaceuticals reported significant clinical benefits from INPEFA in a post hoc analysis, which could positively influence the drug's adoption and sales, potentially impacting LXRX's stock price favorably in the short term.
The announcement of positive clinical trial results typically leads to increased investor confidence in a pharmaceutical company's product, which can result in a short-term stock price increase. Given that INPEFA has already been approved by the FDA, the new data supporting its efficacy could further enhance its market potential and, by extension, Lexicon's financial outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100